The FDA has approved esketamine nasal spray as an adjunctive therapy for adults with treatment-resistant depression (TRD), which affects approximately 30%
New treatment for depression scrutinizedBetsy Mason
Objectives/Introduction Herein we review the evidence supporting Food and Drug Administration (FDA) approved and emerging treatments for bip... RS Mcintyre,DS Cha,RD Kim,... - 《Cns Spectrums》 被引量: 32发表: 2013年 The Epigenetic Code in Depression: Implications for Treatment Major depressive...
Treatment of major depression in standard clinical practice has been an underexamined topic. We studied the management of major depression in psychiatric outpatient care with special reference to the position of the new antidepressants. We sent questionnaires concerning treatment practice of major ...
An increasing number of clinicians and researchers have become interested in the potential of psychedelic drugs for the treatment of mental health disorders, including depression, anxiety, posttraumatic stress disorder, eating disorders, and addictions.1,2 Currently, most psychedelic compounds are illegal ...
What tools can clinicians use to help women make treatment decisions for depression during pregnancy, while breast-feeding, and during perimenopause and menopause? Women constitute two thirds of patients suffering from common depressive disorders, making the treatment of depression in women a substantial...
We conducted the following examination items for all cases in terms of pain and treatment satisfaction at the time of consultation: Visual Analogue Scale (VAS); the Japanese version of the Oswestry Disability Index (ODI)20,21; the Japanese version of the Hospital Anxiety and Depression Scale (H...
Managing patients with treatment-resistant depression (TRD) remains a major challenge for the practicing physician. Depression is considered treatment-resistant when at least two adequate monotherapy trials with drugs from different pharmacologic classes fail to elicit a therapeutic response. Although determin...
EBR speaks to Doug Drysdale of Cybin about the advancements in DMT and studies to find treatments for depression and PTSD. EBR: Do you think that the stigma around psychedelic treatment options is being removed? And if so, or if not, what more could be done to address any remaining stigma...
2023b; Rais et al.2023). Elranatamab has been approved for relapsed or refractory multiple myeloma after four or more prior therapies following priority review, breakthrough, and orphan drug designation (Dhillon2023b). Elranatamab is well tolerated, and the most common non-hematologic treatment-...